Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ATNM is in the long-term down -92% below S&P in 7 years.
Description: Actinium Pharmaceuticals, Inc., a biotechnology company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform. Its products include Bismab-A for acute myeloid leukemia; Actimab-A, an antibody-drug construct that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia; and Iomab-B, an antibody-drug construct used in myeloconditioning for hematopoietic stem cells transplantation in various indications. The company was formerly known as Cactus Ventures, Inc. and changed its name to Actinium Pharmaceuticals, Inc. in April 2013. Actinium Pharmaceuticals, Inc. was founded in 2000 and is based in New York, New York.
|Shares Outstanding||EPS||-0.54||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-2.07|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-55.16%||ROE||-67.28%||ROI|
|Current Ratio||5.52||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.22|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||18.39 M||Cash From Investing Activities||Cash From Operating Activities||-5.81 M||Gross Profit|
|Net Profit||-3.07 M||Operating Profit||-7.87 M||Total Assets||20.06 M||Total Current Assets||19.92 M|
|Total Current Liabilities||3.61 M||Total Debt||190 K||Total Liabilities||3.61 M||Total Revenue|
|High 52 week||1.06||Low 52 week||0.35||Last close||0.65||Last change||1.56%|
|RSI||59.79||Average true range||0.04||Beta||0.95||Volume||288.91 K|
|Simple moving average 20 days||3.74%||Simple moving average 50 days||-2.11%||Simple moving average 200 days||8.43%|
|Performance Week||1.56%||Performance Month||3.75%||Performance Quart||65.86%||Performance Half||-13.25%|
|Performance Year||-30.11%||Performance Year-to-date||-2.05%||Volatility daily||2.99%||Volatility weekly||6.68%|
|Volatility monthly||13.69%||Volatility yearly||47.42%||Relative Volume||353.16%||Average Volume||1.75 M|
|New High||New Low|
2019-03-15 17:05:00 | Actinium Provides Comprehensive Patent Portfolio Update Including New IP Filings
2019-03-07 12:15:09 | What Type Of Shareholder Owns Actinium Pharmaceuticals, Inc.’s NYSEMKT:ATNM?
2019-02-25 14:20:00 | 4 Healthcare Stocks Looking To Kick Off A Strong Week
2019-02-25 08:00:00 | Actinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial
2019-02-21 08:00:00 | Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy
2019-02-15 07:40:00 | Consolidated Research: 2019 Summary Expectations for Caesars Entertainment, Gol Linhas Aereas Inteligentes S.A, Zillow Group, Gladstone Land, Actinium Pharmaceuticals, and Kforce — Fundamental Analysis, Key Performance Indications
2019-02-05 08:00:00 | Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax
2019-01-16 08:00:00 | Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies
2019-01-03 08:00:00 | Actinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco
2018-12-03 08:00:00 | Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate
2018-11-01 09:01:00 | Actinium Pharmaceuticals ASH Annual Meeting Presence to Include Oral Presentation of Feasibility and Safety Results of Iomab-B Pivotal Phase 3 SIERRA Trial and also New Actimab-A Phase 2 Trial Data
2018-10-22 09:30:01 | Has Actinium Pharmaceuticals ATNM Outpaced Other Medical Stocks This Year?
2018-10-22 08:43:12 | Do Options Traders Know Something About Actinium ATNM Stock We Don't?
2018-10-19 08:10:00 | Investor Expectations to Drive Momentum within Motorola Solutions, Shire plc, Bitauto, GRIDSUM HOLDING, GW Pharmaceuticals, and Actinium Pharmaceuticals — Discovering Underlying Factors of Influence
2018-10-16 07:12:11 | Top Ranked Momentum Stocks to Buy for October 16th
2018-10-15 07:21:11 | Top Ranked Momentum Stocks to Buy for October 15th
2018-07-02 07:05:00 | Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks
2018-06-20 08:05:23 | Why Actinium Pharmaceuticals Stock Rose 25.6% on June 18